Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples